http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019053118-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523523e4857f980c860a0d49e77ed0ec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2018-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbf2636ea6bae7b9965be4d73c4dc0c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77000fa66a64b192ffbe084abff7fbef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d61a1dcac753b91f47e01780633b3096 |
| publicationDate | 2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019053118-A1 |
| titleOfInvention | PROADRÉNOMÉDULLINE AS A MARKER OF ABNORMAL PLATELET RATES |
| abstract | The invention relates to a method for the determination, diagnosis, prognosis, treatment advice, treatment monitoring, risk assessment and / or risk stratification of patients with abnormal platelet levels, said method comprising: providing a sample of said patient, determining a level of proadrenomedullin (proADM) or one or more fragments thereof in said sample, said level of pro-ADM or fragment thereof being correlated with platelet levels abnormal in said patient. According to embodiments of the invention, a level of pro-ADM or fragment (s) of the latter of high severity indicates low levels of platelets in the subject and leads to trigger or subsequently modify a treatment of the patient to relieve said disorder. According to some embodiments of the invention, the method comprises determining a rate of one or more additional markers in a sample isolated from the patient, such as platelet count, PCT level, or fragment (s) of the latter, one or more markers of thrombocytopenia and / or one or more markers of an inflammatory response. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020243011-A1 |
| priorityDate | 2017-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1114.